Physician profile
Rafath Humera
NPI 1376871202
$2,842.25
in general payments reported to CMS, 2019-2025
27 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $180 · 2021: $408 · 2022: $415 · 2023: $657 · 2024: $492 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.96 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $430.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $425.72 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.79 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $267.68 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $160.62 | 2019-2025 | Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $141.54 | 2021-2023 | |
| Amgen INC. | $137.28 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $97.94 | 2020-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $94.99 | 2023 | |
| Sanofi-Aventis U.S. LLC | $91.79 | 2021-2022 | |
| Dexcom, INC. | $82.22 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $76.51 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $66.59 | 2023-2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $61.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.68 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $51.50 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $43.30 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.86 | 2019-2023 | Xifaxan, Trulance |
| Medtronic, INC. | $37.28 | 2021 | |
| Ironwood Pharmaceuticals, INC | $24.52 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.10 | 2021 | |
| Mannkind Corporation | $15.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.33 | 2024 | Voquezna |
| Abbott Laboratories | $14.24 | 2023 | Freestyle Libre 3 |
| Vbi Vaccine (Delaware) INC. | $14.19 | 2023 | Prehevbrio |
| Allergan, INC. | $13.28 | 2020 | |
| Scilex Pharmaceuticals INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafath Humera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.